Dermatophytic Onychomycosis Therapeutics Market

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Disease Epidemiology

    4.2. Treatment Regime (Prescription Pattern) 

    4.3. Key Regulation Scenario

    4.4. Pipeline Analysis

    4.5. Reimbursement Scenario

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Per Capita Healthcare Expenditure Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Social Determinants 

        5.2.2. Growing Elderly Population and future Outlook 

        5.2.3. New Market Development For Advanced Products Exhibit Lucrative Growth Opportunities

    5.3. Value Chain

    5.4. Market Dynamics

        5.4.1. Drivers

        5.4.2. Restraints

        5.4.3. Opportunity Analysis

6. COVID19 – Impact Analysis

    6.1. Current COVID19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. Current Economic Projection as compared to 2008 Economic analysis

    6.4. COVID19 and Impact Analysis

        6.4.1. Revenue By Treatment

        6.4.2. Revenue By Indication

        6.4.3. Revenue By Gender

        6.4.4. Revenue By Age Group

        6.4.5. Revenue By Distribution Channel

        6.4.6. Revenue By Country

    6.5. Recovery Scenario – Short term, Midterm and Long Term Impact

7. Global Dermatophytic Onychomycosis Therapeutics Market - Pricing Analysis

    7.1. Regional Pricing Analysis By Product

    7.2. Pricing Break-up

        7.2.1. Manufacturer Level Pricing

        7.2.2. Distributor Level Pricing

    7.3. Average Pricing Analysis Benchmark

8. Global Dermatophytic Onychomycosis Therapeutics Market (Size in US$ Mn) Analysis 2013-2021 and Forecast, 2022-2031

    8.1. Historical Market Value (US$ Mn) Analysis, 2013-2021

    8.2. Current and Future Market Value (US$ Mn) Projections, 2022-2031

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, By Treatment

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2013-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2022-2031

        9.3.1. Drugs

            9.3.1.1. Oral

                9.3.1.1.1. Rx

                9.3.1.1.2. OTC

            9.3.1.2. Topical

                9.3.1.2.1. Rx

                9.3.1.2.2. OTC

        9.3.2. Lasers

            9.3.2.1. Neodymium: yttrium-aluminium-garnet laser (Nd:YAG)

            9.3.2.2. Dual-wavelength near-infrared laser

            9.3.2.3. CO2 Ablative Laser

        9.3.3. Photodynamic Therapy

    9.4. Market Attractiveness Analysis By Treatment

10. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) By Indication, 2013-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2031

        10.3.1. Distal Subungual Onychomycosis

        10.3.2. White Superficial Onychomycosis

        10.3.3. Proximal Subungual Onychomycosis

        10.3.4. Candida Onychomycosis

        10.3.5. Total Dystrophic Onychomycosis

    10.4. Market Attractiveness Analysis By Indication

11. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Gender

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Gender, 2013-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Gender, 2022-2031

        11.3.1. Male

        11.3.2. Female

    11.4. Market Attractiveness Analysis By Gender

12. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Age Group

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2013-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2022-2031

        12.3.1. 0-18 Years

        12.3.2. 18-39 Years

        12.3.3. 40-64 Years

        12.3.4. 65 Years and Above

    12.4. Market Attractiveness Analysis By Gender

13. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Distribution Channelbr />     13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2031

        13.3.1. Institutional Sales

            13.3.1.1. Hospitals

            13.3.1.2. Dermatology Clinics

        13.3.2. Retail Sales

            13.3.2.1. Retail Pharmacies

            13.3.2.2. Drugs Stores

        13.3.3. Mail Order Pharmacies & Online Sales

    13.4. Market Attractiveness Analysis By Gender

14. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Region

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2021

    14.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2031

        14.3.1. North America

        14.3.2. Latin America

        14.3.3. Europe

        14.3.4. East Asia

        14.3.5. South Asia

        14.3.6. Oceania

        14.3.7. Middle East and Africa (MEA)

    14.4. Market Attractiveness Analysis By Region

15. North America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        15.3.1. By Country

            15.3.1.1. U.S.

            15.3.1.2. Canada

        15.3.2. By Treatment

        15.3.3. By Indication

        15.3.4. By Gender

        15.3.5. By Age group

        15.3.6. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Latin America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        16.3.1. By Country

            16.3.1.1. Brazil

            16.3.1.2. Mexico

            16.3.1.3. Argentina

            16.3.1.4. Rest of Latin America

        16.3.2. By Treatment

        16.3.3. By Indication

        16.3.4. By Gender

        16.3.5. By Age group

        16.3.6. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Europe Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        17.3.1. By Country

            17.3.1.1. Germany

            17.3.1.2. Italy

            17.3.1.3. France

            17.3.1.4. U.K.

            17.3.1.5. Spain

            17.3.1.6. BENELUX

            17.3.1.7. Russia

            17.3.1.8. Rest of Europe

        17.3.2. By Treatment

        17.3.3. By Indication

        17.3.4. By Gender

        17.3.5. By Age group

        17.3.6. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. South Asia Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        18.3.1. By Country

            18.3.1.1. India

            18.3.1.2. Thailand

            18.3.1.3. Indonesia

            18.3.1.4. Malaysia

            18.3.1.5. Rest of South Asia

        18.3.2. By Treatment

        18.3.3. By Indication

        18.3.4. By Gender

        18.3.5. By Age group

        18.3.6. By Distribution Channel

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Oceania Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        19.3.1. By Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. By Treatment

        19.3.3. By Indication

        19.3.4. By Gender

        19.3.5. By Age group

        19.3.6. By Distribution Channel

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031

        20.3.1. By Country

            20.3.1.1. GCC Countries

            20.3.1.2. Turkey

            20.3.1.3. South Africa

            20.3.1.4. Rest of Middle East and Africa

        20.3.2. By Treatment

        20.3.3. By Indication

        20.3.4. By Gender

        20.3.5. By Age group

        20.3.6. By Distribution Channel

    20.4. Market Attractiveness Analysis

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Dermatophytic Onychomycosis Therapeutics Market Analysis 2022 & 2031

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.2.1. By Treatment

        21.2.2. By Indication

        21.2.3. By Gender

        21.2.4. By Age group

        21.2.5. By Distribution Channel

    21.3. Canada Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.3.1. By Treatment

        21.3.2. By Indication

        21.3.3. By Gender

        21.3.4. By Age group

        21.3.5. By Distribution Channel

    21.4. Brazil Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.4.1. By Treatment

        21.4.2. By Indication

        21.4.3. By Gender

        21.4.4. By Age group

        21.4.5. By Distribution Channel

    21.5. Mexico Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.5.1. By Treatment

        21.5.2. By Indication

        21.5.3. By Gender

        21.5.4. By Age group

        21.5.5. By Distribution Channel

    21.6. Argentina Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.6.1. By Treatment

        21.6.2. By Indication

        21.6.3. By Gender

        21.6.4. By Age group

        21.6.5. By Distribution Channel

    21.7. Germany Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.7.1. By Treatment

        21.7.2. By Indication

        21.7.3. By Gender

        21.7.4. By Age group

        21.7.5. By Distribution Channel

    21.8. France Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.8.1. By Treatment

        21.8.2. By Indication

        21.8.3. By Gender

        21.8.4. By Age group

        21.8.5. By Distribution Channel

    21.9. U.K. Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.9.1. By Treatment

        21.9.2. By Indication

        21.9.3. By Gender

        21.9.4. By Age group

        21.9.5. By Distribution Channel

    21.10. Spain Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.10.1. By Treatment

        21.10.2. By Indication

        21.10.3. By Gender

        21.10.4. By Age group

        21.10.5. By Distribution Channel

    21.11. BENELUX Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.11.1. By Treatment

        21.11.2. By Indication

        21.11.3. By Gender

        21.11.4. By Age group

        21.11.5. By Distribution Channel

    21.12. Russia Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.12.1. By Treatment

        21.12.2. By Indication

        21.12.3. By Gender

        21.12.4. By Age group

        21.12.5. By Distribution Channel

    21.13. India Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.13.1. By Treatment

        21.13.2. By Indication

        21.13.3. By Gender

        21.13.4. By Age group

        21.13.5. By Distribution Channel

    21.14. Thailand Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.14.1. By Treatment

        21.14.2. By Indication

        21.14.3. By Gender

        21.14.4. By Age group

        21.14.5. By Distribution Channel

    21.15. Indonesia Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.15.1. By Treatment

        21.15.2. By Indication

        21.15.3. By Gender

        21.15.4. By Age group

        21.15.5. By Distribution Channel

    21.16. Malaysia Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.16.1. By Treatment

        21.16.2. By Indication

        21.16.3. By Gender

        21.16.4. By Age group

        21.16.5. By Distribution Channel

    21.17. ASEAN Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.17.1. By Treatment

        21.17.2. By Indication

        21.17.3. By Gender

        21.17.4. By Age group

        21.17.5. By Distribution Channel

    21.18. China Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.18.1. By Treatment

        21.18.2. By Indication

        21.18.3. By Gender

        21.18.4. By Age group

        21.18.5. By Distribution Channel

    21.19. Japan Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.19.1. By Treatment

        21.19.2. By Indication

        21.19.3. By Gender

        21.19.4. By Age group

        21.19.5. By Distribution Channel

    21.20. South Korea Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.20.1. By Treatment

        21.20.2. By Indication

        21.20.3. By Gender

        21.20.4. By Age group

        21.20.5. By Distribution Channel

    21.21. Australia Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.21.1. By Treatment

        21.21.2. By Indication

        21.21.3. By Gender

        21.21.4. By Age group

        21.21.5. By Distribution Channel

    21.22. New Zealand Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.22.1. By Treatment

        21.22.2. By Indication

        21.22.3. By Gender

        21.22.4. By Age group

        21.22.5. By Distribution Channel

    21.23. GCC Countries Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.23.1. By Treatment

        21.23.2. By Indication

        21.23.3. By Gender

        21.23.4. By Age group

        21.23.5. By Distribution Channel

    21.24. South Africa Dermatophytic Onychomycosis Therapeutics Market Analysis

        21.24.1. By Treatment

        21.24.2. By Indication

        21.24.3. By Gender

        21.24.4. By Age group

        21.24.5. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies

    22.2. Market Concentration

    22.3. Market Share Analysis of Top Players

    22.4. Market Presence Analysis

        22.4.1. By Regional footprint of Players

        22.4.2. Product foot print by Players

        22.4.3. Channel Foot Print by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive

        23.3.1. Bausch Health

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.1.4. Sales Footprint

            23.3.1.5. Strategy Overview

                23.3.1.5.1. Marketing Strategy

                23.3.1.5.2. Product Strategy

                23.3.1.5.3. Channel Strategy

        23.3.2. Galderma S.A.

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.2.4. Sales Footprint

            23.3.2.5. Strategy Overview

                23.3.2.5.1. Marketing Strategy

                23.3.2.5.2. Product Strategy

                23.3.2.5.3. Channel Strategy

        23.3.3. Novartis AG

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.3.4. Sales Footprint

            23.3.3.5. Strategy Overview

                23.3.3.5.1. Marketing Strategy

                23.3.3.5.2. Product Strategy

                23.3.3.5.3. Channel Strategy

        23.3.4. Pfizer, Inc.

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.4.4. Sales Footprint

            23.3.4.5. Strategy Overview

                23.3.4.5.1. Marketing Strategy

                23.3.4.5.2. Product Strategy

                23.3.4.5.3. Channel Strategy

        23.3.5. Moberg Pharma AB

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.5.4. Sales Footprint

            23.3.5.5. Strategy Overview

                23.3.5.5.1. Marketing Strategy

                23.3.5.5.2. Product Strategy

                23.3.5.5.3. Channel Strategy

        23.3.6. Bayer AG

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.6.4. Sales Footprint

            23.3.6.5. Strategy Overview

                23.3.6.5.1. Marketing Strategy

                23.3.6.5.2. Product Strategy

                23.3.6.5.3. Channel Strategy

        23.3.7. Dr. Reddy’s Laboratories Ltd.

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.7.4. Sales Footprint

            23.3.7.5. Strategy Overview

                23.3.7.5.1. Marketing Strategy

                23.3.7.5.2. Product Strategy

                23.3.7.5.3. Channel Strategy

        23.3.8. Cipla Ltd.

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.8.4. Sales Footprint

            23.3.8.5. Strategy Overview

                23.3.8.5.1. Marketing Strategy

                23.3.8.5.2. Product Strategy

                23.3.8.5.3. Channel Strategy

        23.3.9. Medimetriks Pharmaceuticals, Inc.

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.9.4. Sales Footprint

            23.3.9.5. Strategy Overview

                23.3.9.5.1. Marketing Strategy

                23.3.9.5.2. Product Strategy

                23.3.9.5.3. Channel Strategy

        23.3.10. Sanofi S.A.

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.10.4. Sales Footprint

            23.3.10.5. Strategy Overview

                23.3.10.5.1. Marketing Strategy

                23.3.10.5.2. Product Strategy

                23.3.10.5.3. Channel Strategy

        23.3.11. GlaxoSmithKline Plc.

            23.3.11.1. Overview

            23.3.11.2. Product Portfolio

            23.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.11.4. Sales Footprint

            23.3.11.5. Strategy Overview

                23.3.11.5.1. Marketing Strategy

                23.3.11.5.2. Product Strategy

                23.3.11.5.3. Channel Strategy

        23.3.12. Teva Pharmaceutical industries Ltd.

            23.3.12.1. Overview

            23.3.12.2. Product Portfolio

            23.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.12.4. Sales Footprint

            23.3.12.5. Strategy Overview

                23.3.12.5.1. Marketing Strategy

                23.3.12.5.2. Product Strategy

                23.3.12.5.3. Channel Strategy

        23.3.13. Cardinal Health Inc.

            23.3.13.1. Overview

            23.3.13.2. Product Portfolio

            23.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.13.4. Sales Footprint

            23.3.13.5. Strategy Overview

                23.3.13.5.1. Marketing Strategy

                23.3.13.5.2. Product Strategy

                23.3.13.5.3. Channel Strategy

        23.3.14. Viatris Inc.

            23.3.14.1. Overview

            23.3.14.2. Product Portfolio

            23.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.14.4. Sales Footprint

            23.3.14.5. Strategy Overview

                23.3.14.5.1. Marketing Strategy

                23.3.14.5.2. Product Strategy

                23.3.14.5.3. Channel Strategy

        23.3.15. Almirall, S.A

            23.3.15.1. Overview

            23.3.15.2. Product Portfolio

            23.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.15.4. Sales Footprint

            23.3.15.5. Strategy Overview

                23.3.15.5.1. Marketing Strategy

                23.3.15.5.2. Product Strategy

                23.3.15.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

List of Tables

Table 01: Reimbursement Analysis for Onychomycosis

Table 02: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 03: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 04: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 05: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 06: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 07: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Region

Table 08: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 09: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 10: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 11: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 12: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 13: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 14: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 15: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 16: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 17: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 18: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 19: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 20: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 21: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 22: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 23: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 24: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 25: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 26: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 27: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 28: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 29: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 30: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 31: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 32: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 33: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 34: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 35: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 36: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 37: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 38: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 39: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 40: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 41: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 42: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 43: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

Table 44: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country

Table 45: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type

Table 46: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication

Table 47: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender

Table 48: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group

Table 49: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

List of Chart

Figure 01: Global Market Value 2022E

Figure 02: Global Market Share 2022E & 2031F

Figure 03: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Treatment Type, 2022E

Figure 04: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Indication, 2022E

Figure 05: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Gender, 2022E

Figure 06: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Age Group, 2022E

Figure 07: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Distribution Channel, 2022E

Figure 08: Global Dermatophytic Onychomycosis Therapeutics Market Historical Market Value and Y-o-Y, 2013-2021

Figure 09: Global Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 10: Onychomycosis Incidence by Income Group (2022E)

Figure 11: Global Onychomycosis Rate by Age Group (2021)

Figure 12: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Treatment Type, 2022-2031

Figure 13: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Oral Drug Treatment, 2022E

Figure 14: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Topical Drug Treatment, 2022E

Figure 15: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Laser Treatment, 2022E

Figure 16: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment Type, 2022E

Figure 17: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Indication, 2022-2031

Figure 18: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Indication, 2022-2031

Figure 19: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022E

Figure 20: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Gender, 2022-2031

Figure 21: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Gender, 2022-2031

Figure 22: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022E

Figure 23: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Age Group, 2022-2031

Figure 24: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Age Group, 2022-2031

Figure 25: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022E

Figure 26: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Distribution Channel, 2022-2031

Figure 27: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Distribution Channel, 2022-2031

Figure 28: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2022E

Figure 29: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Region, 2022-2031

Figure 30: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Region, 2022-2031

Figure 31: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Region, 2022E

Figure 32: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 33: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 34: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 35: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 36: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 37: North America Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 38: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 39: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 40: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 41: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 42: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 43: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 44: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 45: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 46: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 47: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 48: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 49: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 50: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 51: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 52: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 53: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 54: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 55: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 56: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 57: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 58: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 59: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 60: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 61: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 62: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 63: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 64: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 65: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 66: Europe Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 67: Europe Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 68: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 69: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 70: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 71: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 72: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 73: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 74: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 75: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 76: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 77: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 78: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 79: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 80: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 81: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 82: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 83: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 84: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 85: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 86: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 87: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 88: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 89: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 90: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 91: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 92: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 93: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 94: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 95: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 96: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 97: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 98: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 99: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 100: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 101: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 102: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 103: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 104: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 105: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 106: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 107: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 108: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 109: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 110: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 111: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 112: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 113: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 114: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 115: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 116: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)

Figure 117: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)

Figure 118: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)

Figure 119: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)

Figure 120: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)

Figure 121: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)

Figure 122: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016–2022E

Figure 123: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021–2031

Figure 124: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031

Figure 125: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031

Figure 126: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031

Figure 127: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031

Figure 128: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031

Figure 129: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031

Figure 130: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 131: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 132: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 133: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 134: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 135: U.S. Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 136: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 137: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 138: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 139: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 140: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 141: Canada Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 142: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 143: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 144: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 145: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 146: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 147: Brazil Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 148: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 149: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 150: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 151: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 152: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 153: Mexico Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 154: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 155: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 156: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 157: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 158: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 159: Argentina Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 160: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 161: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 162: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 163: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 164: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 165: Argentina Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 166: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 166: Global Onychomycosis Treatment: Brand Share (2022E)

Figure 167: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 168: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 169: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 170: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 171: Germany Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 172: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 173: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 174: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 175: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 176: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 177: France Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 178: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 179: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 180: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 181: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 182: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 183: Spain Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 184: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 185: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 186: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 187: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 188: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 189: Italy Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 190: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 191: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 192: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 193: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 194: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 195: U.K Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 196: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 197: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 198: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 199: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 200: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 201: Benelux Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 202: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 203: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 204: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 205: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 206: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 207: Benelux Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 208: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 209: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 210: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 211: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 212: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 213: Nordics Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 214: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 215: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 216: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 217: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 218: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 219: Russia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 220: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 221: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 222: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 224: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 225: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 225: Poland Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 226: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 227: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 228: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 229: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 230: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 231: India Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 232: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 233: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 234: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 235: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 236: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 237: Thailand Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 238: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 239: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 240: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 241: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 242: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 243: Malaysia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 244: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 245: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 246: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 247: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 248: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 249: Indonesia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 250: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 251: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 252: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 253: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 254: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 255: China Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 256: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 257: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 258: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 259: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 260: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 261: Japan Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 262: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 263: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 264: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 265: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 266: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 267: South Korea Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 268: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 269: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 270: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 271: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 272: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 273: Australia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 274: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 275: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 276: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 277: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 278: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 279: New Zealand Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 280: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 281: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 282: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 283: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 284: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 285: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 286: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031

Figure 287: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031

Figure 288: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031

Figure 289: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031

Figure 290: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031

Figure 291: South Africa Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031

Figure 292: Global Dermatophytic Onychomycosis Therapeutics Market, Absolute $ Opportunity, 2022E –2030

Figure 293: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Treatment Type, 2022-2031

Description

Dermatophytic Onychomycosis Therapeutics Market: Scope of Report

The latest publication by Persistence Market Research on the global dermatophytic onychomycosis therapeutics (DOT) market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2031.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for dermatophytic onychomycosis therapeutics products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the dermatophytic onychomycosis therapeutics market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the dermatophytic onychomycosis therapeutics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the dermatophytic onychomycosis therapeutics market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the DOT market offers information divided into six important segments – treatment type, indication, gender, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Key Questions Answered in Report

• Which regions will continue to remain the most profitable markets for dermatophytic onchomycosis therapeutics over the coming years?
• How will changing trends impact the market?
• How has the COVID-19 crisis impacted market growth?
• How can market players capture the low-hanging opportunities in developed regions?
• What are the strategies of stakeholders in the market to shape their position in this landscape?
• What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
• What are the developmental trends that will impact the market?
• How can companies in the dermatophytic onychomycosis therapeutics industry avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the (DOT market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the dermatophytic onychomycosis therapeutics market are more accurate and reliable.